MyChesCo on MSN

ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam

ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported third-quarter financial results and outlined major clinical milestones that ...